American Invest Hub
  • Politics
  • Investing
  • Business
  • Latest News

American Invest Hub

  • Politics
  • Investing
  • Business
  • Latest News
Business

Humacyte stock may fail to sustain today’s gains: find out more

by admin December 21, 2024
December 21, 2024
Humacyte stock may fail to sustain today’s gains: find out more

Shares of Humacyte Inc (NASDAQ: HUMA) nearly doubled on Friday after receiving full approval for its flagship SYMVESS product from the US Food and Drug Administration (FDA).

Regulatory approval for the company’s bioengineered human tissue marks a major step forward in regenerative medicine and trauma care.

Humacyte stock sure has made its investors a happy lot today – but a more important question is: would it be able to sustain its recent gains heading into the next year?

Unfortunately, there’s reason to believe it may not.  

Insiders have been unloading Humacyte stock

Recent insider moves have not been particularly encouraging in Humacyte.

Brady W. Dougan – its board member who’s married to chief executive Laura Niklason sold a total of 1.5 million shares of Humacyte via his LLC called Ayabudge for $6.6 million in November.   

Insider selling is often considered negative because it signals a lack of confidence in the company’s future prospect.

That’s because executives and board members usually have more information than an average investor.

So, when they trim or sell their stake entirely, it typically suggests they see the stock as overvalued or expect the company to face challenges ahead.

If any of those assumptions prove true, Humacyte stock may end up losing today’s gain over the next few weeks.

HUMA is yet to turn a quarterly revenue

FDA’s approval for Humacyte’s SYMVESS sure is a big news for regenerative medicine.

But one must not forget that it continues to be a pre-revenue company for now. Humacyte lost $39.2 million in its third financial quarter – a significant increase from $26 million a year ago.

The Nasdaq listed firm ended its Q3 with $71 million in cash, cash equivalents, and restricted cash, which suggests it may have to dilute its shareholders to fund operations moving forward.  

What’s also worth mentioning is that Humacyte stock was worth about $3.0 before today’s gain.

So, there’s possibility that investors are manipulating its modest price tag to pump it up before unloading all of it to lock in sizeable profits.

Humacyte faces litigation for misleading investors

Finally, Humacyte is currently grappling with a class-action lawsuit over allegedly misleading investors about the regulatory compliance of its production facilities.

The biotech firm has failed to share critical information with its investors about its business and operations.

If such allegations prove to be true, “the company’s conduct constitutes a serious violation of securities laws,” as per Reed Kathrein of Hagens Berman – a law firm investigating the matter.

And it’s not like Humacyte stock pays a dividend to reward its shareholders for their patience through the turbulence.

Nonetheless, Wall Street has a consensus “buy” rating on Humacyte shares with price targets going as high as $25 at writing.

The post Humacyte stock may fail to sustain today’s gains: find out more appeared first on Invezz

0
FacebookTwitterGoogle +Pinterest
previous post
Why Nike’s CEO believes turnaround efforts could hurt in the short term
next post
Novo Nordisk stock just tanked 25%: here’s what happened

Related Posts

Top FTSE 100 and FTSE 250 shares to...

November 15, 2024

Nvidia CEO Jensen Huang’s net worth swells from...

May 28, 2024

Trump may slash China tariffs to 50% as...

May 9, 2025

Hims & Hers Health says it will offer...

May 22, 2024

Gold jumps to record above $2,460 an ounce...

July 18, 2024

Joy Reid’s net worth at risk as MSNBC...

February 24, 2025

AMC stock price forecast: will it short squeeze...

February 24, 2025

X boss Elon Musk tempers comments about advertisers...

June 24, 2024

Nikkei 225 index outlook ahead of BoJ and...

March 18, 2025

DAX index stable despite tariffs: is it a...

March 28, 2025

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest News

    • Interview: Strategic location gives Brazil Potash cost advantage in domestic fertiliser market, says CEO Matt Simpson

      June 1, 2025
    • Canada’s Q1 GDP expands by 2.2%, driven by exports spike ahead of potential US tariffs

      June 1, 2025
    • President Trump to host farewell for Elon Musk as DOGE leader steps away

      June 1, 2025
    • UK’s digital banks face divergent fortunes: Starling stumbles, Monzo and Revolut soars

      June 1, 2025
    • Trump wants Apple to shift iPhone production from India to the US: here’s what it means

      May 18, 2025

    Categories

    • Business (3,022)
    • Investing (2,459)
    • Latest News (1,994)
    • Politics (1,530)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: americaninvesthub.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 americaninvesthub.com | All Rights Reserved